Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 135989. Отображено 100.
05-01-2012 дата публикации

Tuberculosis antigens, immunogenic compositions, diagnostics and methods related to the same

Номер: US20120003256A1
Принадлежит: Gene Therapy Systems

Provided herein are Mtb polynucleotides, recombinant Mtb peptides and polypeptides, immunogenic Mtb antigens, and Mtb antibodies. Immunogenic compositions are also provided that may be useful as recombinant, subunit and DNA vaccines. In addition the invention provides kits comprising Mtb polynucleotides, Mtb polypeptides, Mtb antibodies, and combinations thereof.

Подробнее
05-01-2012 дата публикации

Particles which are surface coated with hyaluronan or one of the derivatives thereof and the use of same as biological vectors for active substances

Номер: US20120003320A1

Particles comprising a core based on at least one biodegradable organosoluble polymer. At least a part of the surface of the particles is coated with at least one hyaluronan or a derivative thereof, the hyaluronan being a water-soluble, amphiphilic hyaluronan of which the carboxylic functions are in part transformed to form hydrophobic groups.

Подробнее
05-01-2012 дата публикации

High affinity antibodies to human il-6 receptor

Номер: US20120003697A1
Принадлежит: Regeneron Pharmaceuticals Inc

A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a K D of about 500 pM or less and blocks IL-6 activity with an IC 50 of 200 pM or less, is provided. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.

Подробнее
05-01-2012 дата публикации

Homogenous preparations of il-28 and il-29

Номер: US20120004161A1
Принадлежит: Zymogenetics Inc

Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.

Подробнее
05-01-2012 дата публикации

Salt of cd 80 antagonist

Номер: US20120004237A1
Автор: Richard Ian MATTHEWS
Принадлежит: MEDIGENE AG

Choline salt of the CD80 antagonist compound 4-(6-fluoro-3-oxo-1,3-dihydro-pyrazolo[4,3-c]cinnolin-2-yl)-N-(2,2-difluoro-ethyl)-benzamide.

Подробнее
12-01-2012 дата публикации

Transfection of blood cells with mrna for immune stimulation and gene therapy

Номер: US20120009221A1
Принадлежит: CureVac AG

The present invention relates to a pharmaceutical composition containing blood cells or haemopoietic cells, e.g. red blood cells (erythrocytes), granulocytes, mononuclear cells (PBMCs) and/or blood platelets, in combination with a pharmaceutically acceptable excipient and/or vehicle, wherein the cells are transfected with at least one mRNA comprising at least one region coding for at least one antigen. The invention further discloses a method of preparing the aforesaid pharmaceutical composition and the use of blood cells transfected in this way for the preparation of drugs or pharmaceutical compositions for immune stimulation against the antigens encoded by the mRNA. The subjects according to the invention are used especially for the therapy and/or prophylaxis of carcinoses or infectious diseases and can also be employed in gene therapy.

Подробнее
12-01-2012 дата публикации

Modulation of the immune response

Номер: US20120009222A1
Принадлежит: Massachusetts Institute of Technology

The present invention provides lipidoids that can be used to modulate the immune response in a subject. Lipidoids are prepared by the conjugate addition of an amine to an acrylate to acrylamide. The lipidoids form complexes or particles with an immunostimulatory polynucleotide, which are then administerd to a subject. Such compositions have been found to stimulate the production of cytokines and increase both humoral and cell-mediate immune response. The invention also provides pharmaceuti-cal compositions thereof and methods for using the same.

Подробнее
12-01-2012 дата публикации

Preservation of Bioactive Materials By Spray Drying

Номер: US20120009248A1
Автор: Binh Pham, Vu Truong-Le
Принадлежит: MEDIMMUNE LLC

This invention provides methods and compositions to preserve bioactive materials in a matrix of powder particles. Methods provide high-pressure gas spraying and/or near supercritical spraying of formulations followed by drying in a stream of conditioned gas to form stable powder particles containing bioactive materials.

Подробнее
12-01-2012 дата публикации

Non-sedating antihistamine injection formulations and methods of use thereof

Номер: US20120010217A1
Автор: Jie Du
Принадлежит: Individual

Described herein are injectable compositions containing non-sedating or second and third generation antihistamines such as cetirizine/levocetirizine and methods of use thereof. Specifically, methods of treating acute urticaria or angioedema associated with an acute allergic reaction are disclosed. In certain embodiments, the injectable compositions are bioequivalent to currently marketed oral dosage forms with the same number of mg of cetirizine.

Подробнее
12-01-2012 дата публикации

Choline and tromethamine salt of licofelone

Номер: US20120010261A1
Принадлежит: CAIR Biosciences GmbH

The present invention relates to the choline and tromethamine salt of Licofelone.

Подробнее
12-01-2012 дата публикации

Regulatory Elements Associated with CBF Transcription Factors of Maize

Номер: US20120011617A1
Принадлежит: PIONEER HI BRED INTERNATIONAL INC

Compositions and methods for regulating expression of a polynucleotide of interest in a plant are provided. Compositions include novel nucleotide sequences comprising an isolated stress-induced promoter natively linked to the maize ZmCBF2 coding region. A method for expressing a polynucleotide of interest in a plant or plant cell, using a regulatory sequence described herein, is provided. The method may comprise transforming a plant cell to comprise a polynucleotide sequence of interest operably linked to one or more of the regulatory sequences of the present invention and regenerating a stably transformed plant from the transformed plant cell.

Подробнее
19-01-2012 дата публикации

Compositions with reduced dimer formation

Номер: US20120014978A1
Принадлежит: Circassia Ltd

The present invention relates to the use of a non-reducing carbohydrate or carbohydrate derivative and at least one agent which inhibits dimer formation in a freeze-dried composition comprising at least one peptide that contains a free cysteine residue, to provide a freeze-dried composition with improved long-term storage stability.

Подробнее
19-01-2012 дата публикации

Dna vaccine for alzheimer's disease

Номер: US20120014987A1
Автор: Yoh Matsumoto

The present invention aims to provide a DNA vaccine for Alzheimer's disease. The present invention provides a recombinant vector which comprises DNA encoding amyloid β and DNA encoding a Th2 cytokine, as well as a DNA vaccine for Alzheimer's disease which comprises this vector.

Подробнее
19-01-2012 дата публикации

Soybean variety a1024184

Номер: US20120017310A1
Автор: James Behm
Принадлежит: MONSANTO TECHNOLOGY LLC

The invention relates to the soybean variety designated A1024184. Provided by the invention are the seeds, plants and derivatives of the soybean variety A1024184. Also provided by the invention are tissue cultures of the soybean variety A1024184 and the plants regenerated therefrom. Still further provided by the invention are methods for producing soybean plants by crossing the soybean variety A1024184 with itself or another soybean variety and plants produced by such methods.

Подробнее
19-01-2012 дата публикации

Nucleotide sequences and polypeptides encoded thereby useful for modifying plant characteristics

Номер: US20120017330A1
Принадлежит: Ceres Inc

Isolated polynucleotides and polypeptides encoded thereby are described, together with the use of those products for making transgenic plants with increased tolerance to abiotic stress (e.g., high or low temperature, drought, flood).

Подробнее
19-01-2012 дата публикации

Zinc knuckle proteins

Номер: US20120017335A1
Принадлежит: SALK INSTITUTE FOR BIOLOGICAL STUDIES

TZP proteins and method of their use for improving plant characteristics are disclosed.

Подробнее
19-01-2012 дата публикации

Genes regulating plant branching, promotors, genetic constructs containing same and uses thereof

Номер: US20120017337A1

The invention relates to genes coding for TCP family transcription factors and having a biological role in the development of axillary buds and branch growth. Furthermore, the invention relates to the promoters of the transcription of said genes, to the genetic constructs containing same and to the uses thereof, including the use of agents that modulate the expression of these genes in order to modify plant architecture.

Подробнее
26-01-2012 дата публикации

MHC-Less cells

Номер: US20120020885A1
Принадлежит: SEARETE LLC

The present disclosure relates to compositions, methods, systems, computer-implemented methods, and computer program products thereof that relate to biological cells for delivery of at least one therapeutic agent to a biological tissue or subject.

Подробнее
26-01-2012 дата публикации

METHODS FOR TREATING IgE-MEDIATED DISORDER

Номер: US20120020979A1
Автор: Andrea Cerutti, KANG Chen
Принадлежит: CORNELL UNIVERSITY

This invention relates to methods of treating IgE mediated disorders such as allergy and asthma based on activating surface-bound IgD molecules on basophils. The invention also relates to methods of making IgD, as well as methods of screening for antimicrobial agents from IgD-activated basophils.

Подробнее
26-01-2012 дата публикации

Recombinant Anti-VLA4 Antibody Molecules

Номер: US20120022236A1
Принадлежит: BIOGEN IDEC MA INC

The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites of inflammation.

Подробнее
02-02-2012 дата публикации

Immunological herpes simplex virus antigens and methods for use thereof

Номер: US20120027790A1
Принадлежит: UNIVERSITY OF WASHINGTON

The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are antigens and/or their constituent epitopes confirmed to be recognized by T-cells derived from herpetic lesions or from uterine cervix. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.

Подробнее
02-02-2012 дата публикации

Novel lipids and compositions for the delivery of therapeutics

Номер: US20120027796A1
Принадлежит: Alnylam Pharmaceuticals Inc

The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structures: (Formula (I) or (XXXV)).

Подробнее
02-02-2012 дата публикации

Antibody gene transfer and recombinant aav therefor

Номер: US20120027798A1
Принадлежит: Nationwide Childrens Hospital Inc

The present invention relates generally to the use of recombinant adeno-associated viruses (rAAV) for gene delivery and more specifically to the use of rAAV to deliver antibody genes to target cells in mammals. Administration of rAAV encoding antibodies that neutralize the HIV-1 virus is exemplified.

Подробнее
02-02-2012 дата публикации

Compositions and methods for treating or preventing inflammatory bowel disease and colon cancer

Номер: US20120027799A1
Принадлежит: JOHNS HOPKINS UNIVERSITY

The invention provides compositions and methods for useful for the diagnosis of inflammatory bowel disease, ETBF-induced colitis, colonic hyperplasia and/or colon carcinogenesis in a subject in biological samples (e.g., stool, urine, blood, serum, tissue). The invention further provides compositions and methods for the treatment or prevention of colitis, colon cancer, or inflammatory bowel disease (e.g., Crohn's disease).

Подробнее
02-02-2012 дата публикации

Nicotine immunonanotherapeutics

Номер: US20120027808A1
Автор: Matteo Iannacone

The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface having a plurality of nicotine moieties. The invention provides pharmaceutical compositions comprising nanocarriers. The present invention provides methods of designing, manufacturing, and using nanocarriers and pharmaceutical compositions thereof. For example, the present invention describes nanocarriers capable of eliciting an immune response and the production of anti-nicotine antibodies.

Подробнее
09-02-2012 дата публикации

Artificial cells

Номер: US20120034155A1
Принадлежит: SEARETE LLC

The present disclosure relates to various embodiments associated with artificial cells, particularly artificial antigen presenting cells, methods of making the same, methods of administering the same, computer systems relating thereto, computer-implemented methods relating thereto, and associated computer program products.

Подробнее
09-02-2012 дата публикации

Artificial cells

Номер: US20120034157A1
Принадлежит: SEARETE LLC

The present disclosure relates to various embodiments associated with artificial cells, particularly artificial antigen presenting cells, methods of making the same, methods of administering the same, computer systems relating thereto, computer-implemented methods relating thereto, and associated computer program products.

Подробнее
09-02-2012 дата публикации

4'-substituted nucleoside derivatives as inhibitors of hcv rna replication

Номер: US20120034184A1
Принадлежит: Individual

The present invention relates to the use of nucleoside derivatives of formula I wherein B signifies a 9-purinyl residue B1 of formula or a 1-pyrimidyl residue B2 of formula wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof; for the treatment of diseases mediated by the Hepatitis C Virus (HCV), for the preparation of a medicament for such treatment and to pharmaceutical compositions containing such compounds.

Подробнее
09-02-2012 дата публикации

Pharmaceutical composition for treating or preventing cancer by inducing dendritic cell-like differentiation from monocytes to improve anticancer immune activity

Номер: US20120034251A1
Принадлежит: Momotaro Gene Inc

According to the present invention, a composition for inducing or activating dendritic cell-like cells so as to treat or prevent cancer by immunotherapy is provided. Specifically, the following is provided: an agent for activating cancer immunity, which comprises, as an active ingredient, the following REIC protein: (a) a protein consisting of the amino acid sequence shown in SEQ ID NO: 2; or (b) a protein consisting of an amino acid sequence derived from the amino acid sequence shown in SEQ ID NO: 2 by substitution, deletion, or addition of one or more amino acid(s) and having the activity of inducing differentiation from monocytes into dendritic cell-like cells.

Подробнее
09-02-2012 дата публикации

Cell lines producing blocking antibodies to human RANKL

Номер: US20120034690A1
Автор: Dirk M. Anderson
Принадлежит: Immunex Corp

Described herein are cell lines and methods for preparing antibodies that bind RANKL, including cell lines that produce blocking antibodies to human RANKL.

Подробнее
09-02-2012 дата публикации

Sphingo-guanidines and their use as inhibitors of sphingosine kinase

Номер: US20120035268A1

The presently disclosed subject matter provides compounds of the formula: (1) and pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 are as defined herein. Also disclosed are methods for making the compounds of the formula as set forth hereinabove, their use in inhibiting sphingosine kinase, and their use in the treatment and/or prevention of diseases and/or conditions associated with undesirable ceramidase or sphingosine kinase activity, including, but not limit cancer, cancer metastasis, atherosclerosis, stenosis, inflammation, immunological disorders, asthma, atopic dermatitis, wound healing, and other proliferative diseases.

Подробнее
16-02-2012 дата публикации

Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof

Номер: US20120039874A1
Принадлежит: Japan Tobacco Inc

Immunization of human antibody-producing transgenic mice, which have been created using genetic engineering techniques, with AILIM molecule as an antigen resulted in various human monoclonal antibodies capable of binding to AILIM and capable of controlling a variety of biological reactions (for example, cell proliferation, cytokine production, immune cytolysis, cell death, induction of ADCC, etc.) associated with AILIM-mediated costimulatory signal (secondary signal) transduction. Furthermore, it has been revealed that the human monoclonal antibody is effective to treat and prevent various diseases associated with AILIM-mediated costimulatory signal transduction, being capable of inhibiting the onset and/or advancement of the diseases.

Подробнее
16-02-2012 дата публикации

Hydrophobic monomers, hydrophobically-derivatized supports, and methods of making and using the same

Номер: US20120039920A1
Принадлежит: 3M Innovative Properties Co

A composition is disclosed comprising a hydrophobic monomer having the structure: CH 2 ═CR 4 C(O)NHC(R 1 R 1 )(C(R 1 R 1 )) n C(O)XR 3 wherein n is an integer of 0 or 1; R 1 is independently selected from at least one of: a hydrogen atom, alkyls aryls, and alkylaryls, wherein the alkyls, aryls, and alkylaryls have a total of 10 carbon atoms or less; R 3 is a hydrophobic group selected from at least one of: alkyls, aryls, alkylaryls and ethers, wherein the alkyls, aryls, alkylaryls and ethers have a total number of carbon atoms ranging from 4 to 30; R 4 H or CH 3 ; X is O or NH. In some embodiments the hydrophobic monomer is derived from an amine or an alcohol (HXR 3 ) that has a hydrophilicity index of 25 or less. A polymerizable composition comprising the hydrophobic monomer is disclosed, which optionally may comprise a cross-linking monomer and/or a non-cross-linking monomer. This polymerizable mixture may be used to from hydrophobically-derivatized supports, which may be used in applications such as hydrophobic interaction chromatography.

Подробнее
16-02-2012 дата публикации

Methods and compositions for inhibiting cellular proliferation and surgical adhesion

Номер: US20120040928A1
Автор: Rekha Bansal
Принадлежит: Rekha Bansal

A method for inhibiting cellular proliferation of fibroblasts and/or blioma cells in a mammal includes administering a composition to a mammal wherein the composition includes an amount of an anionic polymer and an anti-platelet agent effective to inhibit cellular proliferation of fi- broblasts and gliomas in the mammal

Подробнее
23-02-2012 дата публикации

Pyrimido [5,4-d] pyrimidine derivatives for the inhibition of tyrosine kinases

Номер: US20120046270A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The present invention encompasses compounds of general formula (1), wherein the groups R 1 to R 4 , X 1 , X 2 , X 3 , X 4 , X 5 , Q, L 1 and L 2 are defined as in claim 1 , which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, as well as pharmaceutical preparations and formulations of these compounds.

Подробнее
23-02-2012 дата публикации

Controlled cannabis decarboxylation

Номер: US20120046352A1
Автор: Andrew David Hospodor
Принадлежит: Individual

The invention is a process for the controlled decarboxylation of cannabis wherein Medicinal Delta-9 tetrahydrocannabinol (Δ 9 -THC) and other cannabinoid medicinal substances are decarboxylated through a chemical reaction facilitated by a cofactor. The amount of medicinal cannabis decarboxylated will be directly proportional to the amount of cofactor used. Use a small amount of the cofactor and only some of the medicinal cannabis contained in raw cannabis will be converted from an acidic form into a non-acidic form. Use a large amount of the cofactor and most or all of the medicinal cannabis will be decarboxylated. The reaction is proportional to the molar mass of cofactor.

Подробнее
01-03-2012 дата публикации

Peripheral blood sparc binding antibodies and uses thereof

Номер: US20120052007A1
Принадлежит: Abraxis Bioscience Llc

The invention provides SPARC binding antibodies that have high affinity to SPARC, particularly plasma SPARC, and methods of using such antibodies in treating conditions including cancer.

Подробнее
01-03-2012 дата публикации

Markers and methods for assessing and treating lupus patients susceptible to photoprovocation

Номер: US20120052066A1
Автор: Cesar Calderon, John Getsy
Принадлежит: Centocor Inc

A method for predicting or detecting susceptibility to lupus of an individual subjected to photoprovocation obtains biological samples from the individual before and after exposure to photoprovocation and compares the levels of at least a portion of members of a 45-member panel or subset thereof to determine whether the individual is susceptible to lupus. The method enables identification of potential lupus patients prior to onset of disease symptoms.

Подробнее
01-03-2012 дата публикации

Vaccine composition for prophylaxis and/or therapy of alzheimer's disease

Номер: US20120052086A1
Принадлежит: Hokko Chemical Industry Co Ltd

A vaccine composition for prophylaxis and/or therapy of Alzheimer's disease, which comprises a fusion protein prepared by inserting a single or tandemly repeated multiple copies of amyloid β antigenic peptide having 5 to 15 continuous amino acid residues derived from the N-terminus of amyloid β peptide into a wild type seed storage protein.

Подробнее
01-03-2012 дата публикации

Immunogenic epitopes of ngep antigen

Номер: US20120052116A1

The invention provides a peptide comprising a human cytolytic T lymphocyte (CTL) epitope from the human tumor-associated antigen (TAA) New Gene Expressed in Prostate (NGEP), which can be used in vaccine prevention or therapy of prostate cancer, as well as a nucleic acid encoding the peptide, a vector comprising the nucleic acid, a cell comprising the peptide, nucleic acid, or vector, and compositions thereof.

Подробнее
01-03-2012 дата публикации

ISOLATED GENOMIC POLYNUCLEOTIDE FRAGMENTS FROM THE p15 REGION OF ISOLATED GENOMIC POLYNUCLEOTIDE FRAGMENTS FROM THE p15 REGION OF CHROMOSOME 11 ENCODING HUMAN TUMOR SUPPRESSING SUBTRANSFERABLE CANDIDATE 4 (TSSC4)

Номер: US20120053232A1
Автор: James W. Ryan
Принадлежит: RYOGEN LLC

Provided herein are isolated genomic polynucleotide fragments from the from the p15 region of chromosome 11 encoding human and tumor suppressing subtransferable candidate 4 (TSSC4) and methods of use.

Подробнее
08-03-2012 дата публикации

Geographically Region Specific Allergy Immunotherapy for Companion Animals

Номер: US20120058147A1
Автор: Jonathan D. Plant
Принадлежит: Individual

Implementations and techniques for providing geographically region specific allergy immunotherapy for companion animals are generally disclosed.

Подробнее
08-03-2012 дата публикации

Compositions and methods for elimination of gram negative bacteria

Номер: US20120058936A1

Oral drug delivery formulations which specifically administer antibacterial agents to the ileum, caecum, and/or the colon, without significant administration elsewhere in the gastrointestinal tract, are disclosed. The formulations include, as actives, a combination of a macrolide or aminoglysoside, or quinolone antibacterial and an anti-Gram-negative lipopeptide (polymyxin) antibacterial agent or other peptide antibacterials effective against Gram-negative bacteria. The formulations can be used to treat infections or unwanted colonization in the colon, and to provide effective decontamination of the colonic flora from unwanted or potentially pathogenic bacteria.

Подробнее
08-03-2012 дата публикации

Hmg-coa reductase derived peptide and cosmetic or pharmaceutical composition containing same

Номер: US20120058952A1
Принадлежит: ISP Investments LLC

The present invention relates to a peptide of general formula (I): R 1 -(AA) n -X 1 -Gly-Glu-Leu-Ser-X 2 -X 3- (AA) p -R 2 , derived from human HMG-CoA reductase. The present invention also relates to a cosmetic or pharmaceutical composition comprising at least one peptide of general formula (I), in a physiologically suitable medium. The present invention further relates to the use of this novel peptide as an active principle that activates human HMG-CoA reductase in a cosmetic composition intended to strengthen the barrier function of the skin and to stimulate epidermal differentiation. The invention further applies to a cosmetic treatment method intended to prevent and/or combat the external stresses and signs of cutaneous aging.

Подробнее
08-03-2012 дата публикации

Carbazole carboxamide compounds useful as kinase inhibitors

Номер: US20120058996A1
Принадлежит: Bristol Myers Squibb Co

Compounds having the formula (I), and enantiomers, and diastereomers, pharmaceutically-acceptable salts, thereof, are useful as kinase modulators, including Btk modulation.

Подробнее
08-03-2012 дата публикации

Combinations comprising antimuscarinic agents and pde4 inhibitors

Номер: US20120059031A1
Принадлежит: Individual

A combination which comprises (a) a PDE4 inhibitor and (b) an antagonist of M3 muscarinic receptors which is (3R)-1-phenethyl-3-(9H-xanthene-9carbonyloxy)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid.

Подробнее
08-03-2012 дата публикации

Inhibition of map4k4 through rnai

Номер: US20120059046A1
Принадлежит: RXi Pharmaceuticals Corp

RNAi constructs directed to MAP4K4 that demonstrate unexpectedly high gene silencing activities, and uses thereof are disclosed. The blunt-ended constructs have a double-stranded region of 19-49 nucleotides. The constructs have selective minimal modifications to confer an optimal balance of biological activity, toxicity, stability, and target gene specificity. For example, the strands may be modified (e.g., one or both ends of the sense strand is modified by 2′-O-methyl groups), such that the construct is not cleaved by Dicer or other RNAse III, the antisense strand may also be modified by a 2′-O-methyl group at the penultimate 5′-end nucleotide to greatly reduce off-target silencing.

Подробнее
08-03-2012 дата публикации

Methods and compositions for modification of a hla locus

Номер: US20120060230A1
Принадлежит: Individual

Disclosed herein are methods and compositions for modulating the expression of a HLA locus or for selectively deleting or manipulating a HLA locus or HLA regulator.

Подробнее
15-03-2012 дата публикации

Isotopologues of thalidomide

Номер: US20120064004A1
Принадлежит: Celgene Corp

Provided herein are thalidomide, which is enriched with isotopes such as deuterium. Pharmaceutical compositions comprising the isotopes-enriched compounds, and methods of using such compounds are also provided.

Подробнее
15-03-2012 дата публикации

Il-17 homologous polypeptides and therapeutic uses thereof

Номер: US20120064073A1
Принадлежит: Individual

The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.

Подробнее
15-03-2012 дата публикации

Stabilized biodegradable neurotoxin implants

Номер: US20120065141A1
Принадлежит: Allergan Inc

Biodegradable neurotoxin implants and methods of making and using such implants are provided. Biodegradable neurotoxin implants include a neurotoxin, a biodegradable polymer component, and an acidity regulating component. The biodegradable polymer component is effective in controlling the release of the neurotoxin from the implant when the implant is located in a patient's body. The acidity regulating component is effective in maintaining a pH of the implant in a desired range that may be effective in stabilizing the neurotoxin as the implant biodegrades when the implant is located in a patient's body. In one embodiment, an implant includes a botulinum toxin, a biodegradable polymer, and either monomers from which a biodegradable polymer is derived or oligomers including monomeric units substantially identical to a monomer from which a biodegradable polymer is derived, or a combination of such monomers and oligomers. The oligomers and biodegradable polymer may be derived from a single type of monomer. The implants disclosed herein may be administered to a human or animal patient in which a therapeutic effect is desired for prolonged periods of time.

Подробнее
15-03-2012 дата публикации

Increased Seed Oil and Abiotic Stress Tolerance Mediated by HSI2

Номер: US20120066794A1
Принадлежит: NATIONAL RESEARCH COUNCIL OF CANADA

Increased seed oil content, decreased abscisic acid sensitivity and/or increased drought resistance in a plant may be accomplished by altering expression of a HIGH-LEVEL EXPRESSION OF SUGAR-INDUCIBLE 2 (HSI2) protein in the plant to thereby increase or decrease expression of HSI2 in the plant compared to a plant grown under similar conditions in which the expression of HSI2 was unaltered. Increasing expression of HSI2 increases oil content while decreasing expression of HSI2 decreases abscisic acid sensitivity and/or increases drought resistance.

Подробнее
22-03-2012 дата публикации

Methods of treating inflammation

Номер: US20120070449A1
Принадлежит: Yeda Research and Development Co Ltd

A method of treating an inflammation in a subject in need thereof is disclosed. The method comprising administering to the subject an agent capable of down-regulating an activity or expression of CD151 in a lymphocyte, with the proviso that the agent is not CCL2, thereby treating the inflammation.

Подробнее
22-03-2012 дата публикации

Use of myeloid cell biomarkers for the diagnosis of cancer

Номер: US20120070461A1
Принадлежит: IMMATICS BIOTECHNOLOGIES GMBH

The present invention relates to the use of myeloid cell biomarkers for the differential diagnosis, prognosis, and monitoring of renal cell carcinoma (RCC) or colorectal cancer (CRC). The present invention furthermore relates to monitoring the effect of a treatment against renal cell carcinoma (RCC) or colorectal cancer (CRC), and establishing a prognosis of the outcome of the treatment of renal cell carcinoma (RCC) or colorectal cancer (CRC). The present invention furthermore relates to panels of cellular biomarkers for use in the above methods, in particular multicolor panels for measuring said biomarkers.

Подробнее
22-03-2012 дата публикации

Method of biotechnological production fo bovine hemoderivative and use of bovine hemoderivative

Номер: US20120070463A1
Автор: Dusan Travnicek
Принадлежит: SVUS Pharma AS

The method of biotechnological production of bovine hemoderivative is presented in the following overview providing a summary of individual technological operations in time sequence (Flow-Sheet).

Подробнее
22-03-2012 дата публикации

Targeted multi-epitope dosage forms for induction of an immune response to antigens

Номер: US20120070493A1
Принадлежит: Selecta Biosciences Inc

Provided herein are compositions and methods related to MHC II binding peptides. In some embodiments, the peptides are obtained or derived from a common source. In other embodiment, the peptides are obtained or derived from an infectious agent to which a subject has been repeatedly exposed.

Подробнее
29-03-2012 дата публикации

Hepatitis C Virus Inhibitors

Номер: US20120076755A1
Принадлежит: Enanta Pharmaceuticals Inc

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: Q-G-A-L-B-W  (I), which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Подробнее
29-03-2012 дата публикации

Chloramphenicol Acetyl Transferase (CAT)-Defective Somatostatin Fusion Protein And Uses Thereof

Номер: US20120076806A1
Принадлежит: BRAASCH BIOTECH LLC

Chimeric somatostatin-based polypeptides, polynucleotides used to encode the polypeptides, the methods for isolating and producing the polypeptides and the uses thereof are provided. In addition, low cost adjuvants for enhanced immunogenic response are provided. Vaccinations that include both chimeric somatostatin-based polypeptides and novel adjuvants are included, useful in facilitating farm animal productivity.

Подробнее
29-03-2012 дата публикации

Methods for Synthesizing 3-(Substituted Dihydroisoindolinone-2-YL)-2, 6-Dioxopiperidine, and Intermediates Thereof

Номер: US20120077982A1

The present invention discloses methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2,6-dioxopiperidine and intermediates thereof, namely, the synthesis of compounds of the Formula (I), with each substitutional group defined in the patent specification. Owing to the advantages of high productivity, little influence to the environment and material accessibility, the methods of the present invention is suitable for industrial production.

Подробнее
29-03-2012 дата публикации

Yield Enhancement in Plants by Modulation of a ZM-LOBDP1 Protein

Номер: US20120079622A1
Автор: Guofu Li
Принадлежит: PIONEER HI BRED INTERNATIONAL INC

Compositions and methods for modulating plant development and for increasing yield in a plant are provided. The compositions include a ZM-LOBDP1 sequence. Compositions of the disclosure comprise amino acid sequences and nucleotide sequences selected from SEQ ID NOS: 1 and 2 as well as variants and fragments thereof. Nucleotide sequences encoding the ZM-LOBDP1 molecule are provided in DNA constructs for expression in a plant of interest are provided for modulating the level of a ZM-LOBDP1 sequence in a plant or a plant part are provided. The methods comprise introducing into a plant or plant part a heterologous polynucleotide comprising a ZM-LOBDP1 sequence of the disclosure. The level of the ZM-LOBDP1 polypeptide can be increased or decreased. Such method can be used to increase the yield in plants; in one embodiment, the method is used to increase grain yield in cereals.

Подробнее
29-03-2012 дата публикации

Yield Enhancement in Plants by Modulation of a ZM-ZFP1 Protein

Номер: US20120079623A1
Автор: Guofu Li
Принадлежит: PIONEER HI BRED INTERNATIONAL INC

Compositions and methods for modulating plant development and for increasing yield in a plant are provided. The compositions include a ZM-ZFP1 sequence. Compositions of the disclosure comprise amino acid sequences and nucleotide sequences selected from SEQ ID NOS: 1 and 2 as well as variants and fragments thereof. Nucleotide sequences encoding the ZM-ZFP1 molecule are provided in DNA constructs for expression in a plant of interest are provided for modulating the level of a ZM-ZFP1 sequence in a plant or a plant part are provided. The methods comprise introducing into a plant or plant part a heterologous polynucleotide comprising a ZM-ZFP1 sequence of the disclosure. The level of the ZM-ZFP1 polypeptide can be increased or decreased. Such method can be used to increase the yield in plants; in one embodiment, the method is used to increase grain yield in cereals.

Подробнее
29-03-2012 дата публикации

Compositions and methods for modulation of plant cell division

Номер: US20120079628A1
Принадлежит: UNIVERSITY OF WASHINGTON

The present invention provides compositions and methods for modulating cell division in plants. In particular, the present invention provides polynucleotides that encode REVOLUTA. In addition, REVOLUTA vectors and transformed plants are provided wherein plant cell division is modulated by expression of a REVOLUTA transgene as compared to a control population of untransformed plants. The present invention also provides methods for the isolation and identification of REVOLUTA genes from higher plants.

Подробнее
05-04-2012 дата публикации

Cd33 binding agents

Номер: US20120082670A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The present invention relates to immunotherapies that are based on myeloid cell depletion. In particular, the present invention relates to CD33 binding agents for use in such therapies, e.g. in the treatment of myeloid cell malignancies and myelodysplastic syndrome (MDS).

Подробнее
05-04-2012 дата публикации

In Vitro Generation of Myeloid Derived Suppressor Cells

Номер: US20120082688A1
Принадлежит: Mount Sinai School of Medicine

The invention relates to methods of isolating, culturing, and differentiating myeloid derived suppressor cells (MD-SCs) from embryonic stem (ES) cells and hematopoietic stem cells (HSCs). In certain embodiments, the invention relates to methods and compositions for producing MDSCs from ES cells and HSCs using a combination of factors including macrophage colony-stimulating factor (M-CSF).

Подробнее
05-04-2012 дата публикации

Photochrome- or near ir dye-coupled polymeric matrices for medical articles

Номер: US20120082713A1
Принадлежит: Surmodics Inc

The invention provides polymers comprising pendent photochrome or near IR dye groups, as well as polymeric matrices made from these polymers, which can be used as or in association with a medical article. The polymers can be synthesized using methods that facilitate the preparation of medical articles having good biocompatibility. Exemplary polymeric matrices are in the form of lubricious coatings on medical devices, such as catheters. Visualization by irradiation of the photochrome or near IR dye can improve detection of the polymeric matrix on a device or in the body. This, in turn can improve aspects of a medical procedure, such as device insertion or matrix formation, as well as being useful for assessing the quality of the matrix.

Подробнее
05-04-2012 дата публикации

Emulsion Method For Preparing Low Residual Solvent Microparticles

Номер: US20120083444A1
Принадлежит: Surmodics Pharmaceuticals Inc

The method disclosed herein comprises using a non-polar alkane in the continuous phase of an emulsion process to aid in the removal of dispersed phase solvent from the microparticles. The microparticles can further be subjected to a post-production treatment process, involving a non-polar alkane suspension and a rinse, to further reduce residual dispersed phase solvent levels.

Подробнее
05-04-2012 дата публикации

Compositions Containing HC-HA Complex and Methods of Use Thereof

Номер: US20120083445A1
Автор: Hua He, Scheffer Tseng
Принадлежит: TissueTech Inc

Disclosed herein, in certain embodiments, is an HC•HA complex comprising hyaluronan and a heavy chain of IαI, wherein the transfer of the heavy chain of IαI is catalyzed by TSG-6. Further disclosed herein, in certain embodiments, is an HC•HA complex comprising hyaluronan and a heavy chain of IαI, wherein the transfer of the heavy chain of IαI is catalyzed by the TSG-6 like protein. Additionally, disclosed herein are methods of manufacturing said complex and methods of use thereof

Подробнее
05-04-2012 дата публикации

Methods of using il-31 to treat chronic obstructive pulmonary disease (copd)

Номер: US20120083456A1
Принадлежит: Zymogenetics Inc

Use of IL-31 agonists, including IL-31, are used to treat agonists are used to treat asthma, airway hyper-responsiveness or allergic rhinitis. The method comprise inhibiting, reducing, limiting or minimizing production of proinflammatory cytokines and include administration of the IL-31 agonist during sensitization or challenge resulting in the asthma, airway hyper-responsiveness or allergic rhinitis state.

Подробнее
12-04-2012 дата публикации

Nasal spray device

Номер: US20120085345A1

A nasal spray device for the delivery of a pharmaceutical formulation to the nasal cavity in metered doses. The device includes: a pressurised aerosol canister including a vial containing a pharmaceutical formulation including an active ingredient, a propellant and, optionally, a co-solvent, the aerosol canister further including a metering valve having a valve stem; and an actuator for the aerosol canister, the actuator including a stem block having a receptacle into which the valve stem of metering valve of the aerosol canister is received and axially located and being displaceable relative to the vial of the aerosol canister to actuate the metering valve of the aerosol canister, a sump extending below the receptacle, the stem block further defining a discharge orifice for the pharmaceutical formulation and a transfer channel through which a dispensed dose of the pharmaceutical formulation is able to pass from the sump to the discharge orifice.

Подробнее
12-04-2012 дата публикации

Novel caviidae allergens and uses thereof

Номер: US20120087870A1
Принадлежит: Individual

The present invention relates to the provision of a nucleic acid molecule encoding a Caviidae allergen comprising a polynucleotide selected from the group consisting of (a) a polynucleotide sequence as shown in SEQ ID NO 1 (Cav p 3), SEQ ID NO 5 (Cav p 2), SEQ ID NO 3 (Cav p 6) or SEQ ID NO 19 ( Cavia porcellus allergen 1 a) or a fragment thereof, (b) a polynucleotide sequence encoding a polypeptide as shown in SEQ ID NO 2 (Cav p 3), SEQ ID NO 6 (Cav p 2), SEQ ID NO 4 (Cav p 6) or SEQ ID NO 20 ( Cavia porcellus allergen 1 a) or a fragment thereof (c) a polynucleotide sequence which has at least 80% identity to the polynucleotides as defined in (a) or (b) encoding a Caviidae allergen or a fragment thereof, (d) a polynucleotide sequence encoding a polypeptide which has at least 85% identity to the polypeptide as shown in SEQ ID NO 2 (Cav p 3), SEQ ID NO 6 (Cav p 2), SEQ ID NO 4 (Cav p 6) or SEQ ID NO 20 ( Cavia porcellus allergen 1 a ) or a fragment thereof, (e) a polynucleotide sequence which hybridizes to the polynucleotide sequence of any one of (a) to (d) and whereby the coding strand encodes a Caviidae allergen or a fragment thereof, (f) a polynucleotide sequence encoding a polypeptide as encoded by the nucleotide sequence of any one of (a) to (e) wherein at least one amino acid is deleted, substituted inserted or added and whereby said polynucleotide encodes a Caviidae allergen or a fragment thereof, and (g) a polynucleotide sequence being degenerate as a result of the generic code to the polynucleotide sequence as defined in any one of (a) to (f) The present invention also provides for a method for producing the polypeptides (Cav p3, Cav p6, Cavia porcellus allergen 1 a) encoded by said polynucleotides Moreover, the use of such allergens in a medical setting (e g in form of a pharmaceutical and/or diagnostic composition) an in vitro method for determining the allergenicity to Caviidae as well as an method for identifying potential antagonists or agonists of the ...

Подробнее
12-04-2012 дата публикации

Therapeutic and diagnostic anti-hsp70 antibodies

Номер: US20120087931A1
Автор: Gabriele Multhoff
Принадлежит: Multimmune GmbH

Methods and compositions for the detection, prevention and treatment of infectious diseases, primary and metastatic neoplastic diseases, including, but not limited to human sarcomas and carcinomas are described. In particular, specific antibodies are provided, which are capable of binding an epitope of Hsp70 that is extracellularly localized on diseased tissue and cells, in particular on tumor cells and infected cells.

Подробнее
12-04-2012 дата публикации

Inhibitors of protein tyrosine phosphatases

Номер: US20120088720A1

Disclosed herein are compounds that selectively inhibit members of the PTP family of enzymes. Synthesized compounds demonstrated selective inhibition of TC-PTP. Also provided are methods of using the compounds and formulations containing the compounds. Also described is a fluorescence-tagged combinatorial library synthesis and screening method. And methods of using these compounds to effect enzyme activity both in cells and in vitro as well as method of using these compounds to treat diseases in human and animals.

Подробнее
19-04-2012 дата публикации

Treatment of autoimmune disorders with a neurotoxin

Номер: US20120093827A1
Принадлежит: Allergan Inc

Methods of treating one or more autoimmune disorders include a step of administering a Clostridial neurotoxin, such as a botulinum toxin, to a patient that has an autoimmune disorder. In one aspect, a method includes a step of administering the neurotoxin to the thymus gland or near the thymus gland of the patient. In another aspect, a method includes a step of administering the neurotoxin in combination with administering a cytokine inhibitor to the patient. Compositions are also described.

Подробнее
19-04-2012 дата публикации

Tat-Based Tolerogen Compositions and Methods for Making and Using Same

Номер: US20120093858A1
Автор: David I. Cohen
Принадлежит: PIN Pharma Inc

A Tat-based tolerogen composition comprising at least one immunogenic antigen coupled to at least one human immunodeficiency virus (HIV) trans-activator of transcription (Tat) molecule wherein the immunogenic antigen can be a foreign or endogenous antigen or fragments thereof. Additionally methods of suppressing organ transplant rejection and methods of treating autoimmune diseases are provided.

Подробнее
19-04-2012 дата публикации

Method For Polypeptide Transfer Into Cells

Номер: US20120093872A1
Принадлежит: Lophius Biosciences GmbH

The present invention relates to a method for polypeptide transfer into cells. The present invention further relates to the detection of polypeptide-specific immune cells and the priming, expansion and reactivation of polypeptide-specific T cells. Moreover the present invention relates to polypeptides of the methods of the present invention in combination with urea and their use for research, diagnosis or treatment and prevention of diseases in animals and humans.

Подробнее
19-04-2012 дата публикации

Implantable liposome embedded matrix composition, uses thereof, and polycaprolactone particles as scaffolds for tissue regeneration

Номер: US20120093914A1
Принадлежит: MOMA THERAPEUTICS

In various embodiments, the present invention describes materials and methods for the local reprogramming of cells in a location where the treatment is applied. The invention can be used to replace lost cells or to restore function to tissue damaged due to disease, injury or genetic defect. In various embodiments, the treatment includes a semisolid hydrogel embedded with liposomes. The liposomes can contain an effector molecule or molecules. When phagocytic cells such as monocytes infiltrate the hydrogel, they encounter the liposomes and incorporate the liposomes carrying the effector molecules into the cells. In some embodiments, the effector molecules can be genetic material encoding the expression of specific proteins such as transcription factors, the expression of which can initiate the reprogramming of the cells. In other embodiments, the effector molecules can induce angiogenesis. In other embodiments, the effector molecules are tumor antigens. The matrix can contain other effector molecules designed to attract specific cells to the matrix. The cells can be released from the matrix as the matrix degrades or by active migration from the matrix. The cells can also remain in the matrix and secret molecules such as proteins and hormones that will diffuse through the matrix material to the surrounding tissue.

Подробнее
19-04-2012 дата публикации

Neutrophil-depleted platelet rich plasma formulations for cardiac treatments

Номер: US20120093941A1
Автор: Allan Kumar Mishra
Принадлежит: Allan Kumar Mishra

Compositions and methods for preparing neutrophil-depleted platelet rich plasma are provided. Generally, these compositions comprise a higher concentration of platelets and depressed concentrations of neutrophils relative to whole blood although white blood cells may be at higher concentrations than whole blood. The concentrations of the platelets and/or the white blood cells may be two to eight times the respective concentrations in whole blood. These compositions may have depressed concentrations of red blood cells and hemoglobin. In some variations, the compositions may be useful to treat damaged connective tissue and/or to slow or stop cardiac apoptosis after a heart attack. The neutrophil-depleted platelet rich plasma composition may be delivered in conjunction with reperfusion therapy.

Подробнее
19-04-2012 дата публикации

Derivatives of apf and methods of use

Номер: US20120094933A1

Derivatives of bladder epithelial antiproliferative factor and methods of using them are disclosed. In specific embodiments, the glycopeptide compositions are useful for the treatment and/or prevention of medical conditions, including cancer. In other embodiments, there are compositions and methods related to treatment of bladder conditions. In particular embodiments, the glycopeptide comprises D-pipecolic acid or L-pipecolic acid.

Подробнее
19-04-2012 дата публикации

Pyrido [5, 4-d] pyrimidines as cell proliferation inhibitors

Номер: US20120094975A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The present invention encompasses compounds of general formula (1) wherein the groups R 1 to R 4 , X 1 , X 1 , X 3 , L 1 and L 2 are defined as in claim 1 , which are suitable for the treatment of diseases characterised by excessive or anomalous cell pro-liferation, and the use thereof in such a treatment.

Подробнее
19-04-2012 дата публикации

Novel lipids and compositions for the delivery of therapeutics

Номер: US20120095075A1
Принадлежит: Alnylam Pharmaceuticals Inc

The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structure:

Подробнее
26-04-2012 дата публикации

Anti-human cd52 immunoglobulins

Номер: US20120100152A1
Принадлежит: Genzyme Corp

The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a humanized immunoglobulin or immunoglobulin light chain or heavy chain, and to a method of preparing a humanized immunoglobulin. The humanized immunoglobulins can be used in therapeutic applications to treat, for example, autoimmune disease, cancer, non-Hodgkin's lymphoma, multiple sclerosis and chronic lymphocytic leukemia.

Подробнее
26-04-2012 дата публикации

Continuous Cell Programming Devices

Номер: US20120100182A1
Принадлежит: Individual

The present invention comprises compositions, methods and devices for creating an infection-mimicking environment within a polymer scaffold to stimulate antigen-specific dendritic cell activation. Devices of the present invention are used to provide protective immunity to subjects against infection and cancer.

Подробнее
26-04-2012 дата публикации

Inhibition of secretion from non-neuronal cells

Номер: US20120101027A1
Принадлежит: Syntaxin Ltd

The present invention relates to treatment of disease by inhibition of cellular secretory processes, to agents and compositions therefor, and to manufacture of those agents and compositions. The present invention relates particularly, to treatment of disease dependent upon the exocytotic activity of endocrine cells, exocrine cells, inflammatory cells, cells of the immune system, cells of the cardiovascular system and bone cells.

Подробнее
26-04-2012 дата публикации

Pure isomers of tritoqualine

Номер: US20120101120A1
Принадлежит: Individual

The invention provides an isolated stereoisomer of tritoqualine having the structure of FIG. 2 and FIG. 3.

Подробнее
26-04-2012 дата публикации

Locally targeted anti-fibrotic agents and methods of use

Номер: US20120101325A1
Принадлежит: Kyphon SARL

Effective devices and methods using an antifibrotic agent are provided for treating fibrosis or treating normal fibrous tissue. The devices and methods comprise an antifibrotic agent to degrade shrink, relax or stretch at least a portion of the fibrotic tissue. In some embodiments, the methods and devices are configured to immediately release an effective amount of the antifibrotic agent within 24 hours. In some embodiments, when the device comes in contact directly or indirectly with an activator, the antifibrotic agent will be immediately released from the depot. In some embodiments, the depot provides sustained release of the antifibrotic agent over a period of up to one year to treat fibrous tissue.

Подробнее
03-05-2012 дата публикации

Synthetic Oligopeptides Designed From Mite Cysteine Proteases and Methods for the Production of

Номер: US20120107335A1

The invention refers to the design, synthesis and evaluation of 6 synthetic oligopeptides, that have not been previously described, designed from the T and B epitopes of allergens of group I of intradomiciliary mites of the species Dermatophagoides pteronyssinus, Dermatophagoides farinae and Blomia tropicalis , which can be used in the immunomodulation of individuals having immunocompetent systems and in the production of IgY polyclonal antibodies. The invention relates to a first method for obtaining a composition of IgY polyclonal antibodies that can be used as a diagnostic reagent having low cost and high reactivity in respect of intradomiciliary mites, and a second method for the detection of mite allergens, using the IgY antibody composition developed in the first method. The invention further relates to the composition of the IgY polyclonal antibodies.

Подробнее
03-05-2012 дата публикации

Ex vivo animal or challenge model as method to measure protective immunity directed against parasites and vaccines shown to be protective in the method

Номер: US20120107342A1

Described is an ex vivo animal or challenge model used as a method to identify protective (e.g., recombinant) proteins and rapidly measure protective immunity in intestinal segments directed against parasites and vaccines directed against parasitic infections. Further described are vaccines directed against infection with parasites, such as Fasciola hepatica , which vaccines contain protective (recombinant) proteins identified and shown to be protective in studies using the ex vivo model. Further described are protective (e.g., recombinant) proteins obtained from newly excysted juveniles (NEJ) of F. hepatica . The protective (recombinant) protein corresponding to an NEJ protein has an apparent molecular weight of 32 kD and an N-terminal amino acid molecule comprising the sequence XXDVSWPFWDRMYNY (SEQ ID NO:1).

Подробнее
10-05-2012 дата публикации

Cd4+cd25- t cells and tr1-like regulatory t cells

Номер: US20120114597A1
Принадлежит: Merix Bioscience Inc

The invention provides CD4 + CD25 − T cells and Tr1-like regulatory T cells (i.e., contact-independent Type 1-like regulatory T cells), processes for their production and their use for regulatory purposes.

Подробнее
10-05-2012 дата публикации

Ifn-alpha/beta-independent mechanism of antiviral protection through a novel ligand-receptor pair: ifn- ligands engage a novel receptor ifn-rn (crf2-12) and il-10r2 (crf2-4) for signaling andinduction of biological activities

Номер: US20120114603A1

A novel IFN-α/β independent ligand receptor system which upon engagement leads, among other things, to the establishment of an anti-viral state is disclosed. Further disclosed are three closely positioned genes on human chromosome 19 that encode distinct but highly homologous proteins, designated IFN-λ1, IFN-λ2, IFN-λ3, based, inter alia, in their ability to induce antiviral protection. Expression of these proteins is induced upon viral infection. A receptor complex utilized by all three IFN-λ proteins for signaling is also disclosed. The receptor complex is generally composed of two subunits, a novel receptor designated IFN-λR1 or CRF2-12, and a second subunit, IL-10R2 or CRF2-4, which is also a shared receptor component for the IL-10 and IL-22 receptor complexes. The gene encoding IFN-λR1 is generally widely expressed, including many different cell types and tissues. Expression of these proteins is induced by immune events, including, for example, upon viral infection. Apoptotosis may also be induced under effective conditions.

Подробнее
10-05-2012 дата публикации

Compositions comprising angiogenic factors and methods of use thereof

Номер: US20120114685A1
Принадлежит: University of Pennsylvania Penn

The present invention provides recombinant Listeria strains comprising an angiogenic factor, recombinant polypeptides comprising an angiogenic factor operatively linked to a polypeptide comprising a PEST-like sequence, recombinant nucleotide molecules encoding same, related vaccines, and immunogenic and therapeutic methods utilizing same.

Подробнее
10-05-2012 дата публикации

Sparc-derived tumor rejection antigenic peptides and medicaments comprising the same

Номер: US20120115221A1
Принадлежит: ONCOTHERAPY SCIENCE INC

It is an objective of the present invention to identify SPARC protein-derived peptides that are able to induce human killer T cells and helper T cells having cytotoxic activity to tumors, and to provide a means for carrying out a tumor immunotherapy of patients with various types of cancers overexpressing SPARC. The present invention provides a peptide of any of the following: (A) a peptide which consists of the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3; or (B) a peptide which consists of an amino acid sequence comprising a substitution or addition of one or several amino acids with respect to the peptide consisting of the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3, and which has capacity to induce cytotoxic (killer) T cells.

Подробнее
10-05-2012 дата публикации

Use of total coumarins of cnidium fruit in preparing medicaments for treating psoriasis

Номер: US20120115940A1
Автор: Liping Yang
Принадлежит: Individual

A pharmaceutic composition for treating psoriasis. Ii has an active component and a carrier. The active component has a major active ingredient osthol and a group of minor active ingredients: xanthotoxol, xanthotoxin, isopimpinellin, bergapten, and imperatorine. The major active ingredient osthol accounts for at least 90% by weight of the active component, which accounts for 5-35% by weight of the overall pharmaceutic composition.

Подробнее
10-05-2012 дата публикации

Acrylamide Derivative And Use Thereof In Manufacture Of Medicament

Номер: US20120116075A1
Автор: Shuping Sun

An acrylamide derivative represented by formula (I), pharmaceutically acceptable salts and solvates thereof, as well as a medicament containing said acrylamide derivative or its pharmaceutically acceptable salts as the active ingredient, which can be used to treat disorders associated with tyrosine kinase especially Bcr-Abl, including proliferative disorders such as cancers, and inflammation and the like are provided.

Подробнее
17-05-2012 дата публикации

Compositions and methods for immunostimulatory rna oligonucleotides

Номер: US20120121551A1
Принадлежит: Gunther Hartmann

The present invention provides 4-nucleotide (4mer) RNA motifs that confer immunostimulatory activity, in particular, IFN-α-inducing activity to a RNA oligonucleotide. The present invention also provides RNA oligonucleotides, including siRNA, with high or low immunostimulatory activity. The present invention further provides the use of the RNA oligonucleotides of the invention for therapeutic purposes.

Подробнее
17-05-2012 дата публикации

Antibodies that immunospecifically bind to b lymphocyte stimulator protein

Номер: US20120121606A1
Принадлежит: Human Genome Sciences Inc

The present invention relates to antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention also relates to methods and compositions for detecting or diagnosing a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate function of B Lymphocyte Stimulator comprising antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate B Lymphocyte Stimulator function comprising administering to an animal an effective amount of one or more antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator.

Подробнее
17-05-2012 дата публикации

Promoters for recombinant viral expression

Номер: US20120121617A1
Принадлежит: Bavarian Nordic AS

The invention relates to a promoter selected from a group of nucleic acids consisting of (a) a nucleic acid having the nucleotide sequence of SEQ ID NO:1; (b) a nucleic acid having a nucleotide sequence derived from SEQ ID NO:1, wherein not more than 10 nucleotides have been added, deleted, substituted and/or inverted from the nucleic acid of SEQ ID NO:1; and (c) a nucleic acid sequence having at least 70% identity with the nucleic acid of (a); wherein the promoter has a length of up to and including 27 nucleotides and wherein the promoter according to options (b) and (c) exhibits at least the 70% of the promoter activity of SEQ ID NO:1 as measured by the amount of recombinant protein produced.

Подробнее
17-05-2012 дата публикации

Tat-Based Vaccine Compositions and Methods of Making and Using Same

Номер: US20120121636A1
Автор: David I. Cohen
Принадлежит: NANIRX Inc

A Tat-based vaccine composition comprising at least one antigen coupled to at least one immunostimulatory lentivirus trans-activator of transcription (Tat) molecule wherein the antigen is a cancer antigen an infectious disease antigen or a fragment thereof and methods to treat disease by administering the Tat-based vaccine composition. An additional Tat-based vaccine composition comprising immunostimulatory lentivirus Tat is provided.

Подробнее
17-05-2012 дата публикации

Compositions and methods for the prevention and treatment of cancer

Номер: US20120121649A1
Автор: Pedro Santamaria
Принадлежит: UTI LP

Conventional cancer immunotherapy falls short at efficiently expanding T cells that specifically target cancerous cells in numbers sufficient to significantly reduce the tumor size or cancerous cell number in vivo. To overcome this limitation, provided herein are nanoparticles coated with MHC class I and/or class II molecules presenting tumor-specific antigens and co-stimulatory molecules and their use to expand antigen-specific anti-tumorigenic T cells to levels not achieved in current immunotherapeutic techniques. These antigen-specific anti-tumorigenic T cells include cytotoxic T cells, effector T cells, memory T cells, and helper T cells that are necessary to initiate and maintain a substantial immune response against metastatic or non-metastatic cancerous, pre-cancerous, or neoplastic cells in vivo. The present invention describes a systemic approach to targeting cancerous or pre-cancerous cells that are circulating cells, as in lymphomas, migratory metastatic cells, and solid tumors.

Подробнее
17-05-2012 дата публикации

Small interfering rna delivery

Номер: US20120121689A1
Принадлежит: Lipoxen Technologies Ltd

A liposomal siRNA composition is described. The liposomes are formed of neutral liposome forming components, and the composition comprising additionally sugar. The composition provides reduced expression of target gene, without causing systemic toxicity. The composition is produced by a dehydration-rehydration technique to provide high yields and good control of liposome size.

Подробнее
17-05-2012 дата публикации

Agents and Methods Related to Reducing Resistance to Apoptosis-Inducing Death Receptor Agonists

Номер: US20120122724A1
Принадлежит: UAB RESEARCH FOUNDATION

Provided herein is a method of reversing or preventing a target cell's resistance to a death receptor agonist. Also provided are methods of screening for biomarkers resistance of and monitoring resistance to death receptor agonists. Also provided are methods of selectively inducing apoptosis in a target cell, treating a subject with cancer, autoimmune or inflammatory diseases, comprising administering compositions provided herein. Further provided are compositions comprising agents that modulate CARD containing proteins.

Подробнее